Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Chemed Inc (CHE)

Chemed Inc (CHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,561,402
  • Shares Outstanding, K 15,139
  • Annual Sales, $ 2,264 M
  • Annual Income, $ 272,510 K
  • 60-Month Beta 0.46
  • Price/Sales 3.80
  • Price/Cash Flow 23.14
  • Price/Book 7.27
Trade CHE with:

Options Overview Details

View History
  • Implied Volatility 13.89% ( -0.29%)
  • Historical Volatility 25.71%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 23.17% on 10/19/23
  • IV Low 13.89% on 05/17/24
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 2.03
  • Today's Open Interest 236
  • Open Int (30-Day) 206

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 5.22
  • Number of Estimates 2
  • High Estimate 5.38
  • Low Estimate 5.05
  • Prior Year 4.71
  • Growth Rate Est. (year over year) +10.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
556.88 +1.55%
on 05/03/24
622.33 -9.13%
on 04/24/24
-38.65 (-6.40%)
since 04/17/24
3-Month
556.88 +1.55%
on 05/03/24
654.62 -13.61%
on 03/15/24
-17.91 (-3.07%)
since 02/16/24
52-Week
492.84 +14.75%
on 09/13/23
654.62 -13.61%
on 03/15/24
+25.10 (+4.64%)
since 05/17/23

Most Recent Stories

More News
Chemed: Q1 Earnings Snapshot

Chemed: Q1 Earnings Snapshot

CHE : 565.52 (-0.50%)
Chemed: Q4 Earnings Snapshot

Chemed: Q4 Earnings Snapshot

CHE : 565.52 (-0.50%)
Chemed: Q3 Earnings Snapshot

Chemed: Q3 Earnings Snapshot

CHE : 565.52 (-0.50%)
Chemed: Q2 Earnings Snapshot

Chemed: Q2 Earnings Snapshot

CHE : 565.52 (-0.50%)
DVA vs. CHE: Which Stock Should Value Investors Buy Now?

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA : 139.82 (+2.45%)
CHE : 565.52 (-0.50%)
Chemed Corporation to Present at the Bank of America Merrill Lynch 2023 Health Care Conference

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Merrill Lynch 2023 Health Care Conference on Wednesday, May 10, 2023, at 10:40 AM (PDT) at the Encore...

CHE : 565.52 (-0.50%)
AmerisourceBergen (ABC) Beats on Q2 Earnings, Ups '23 EPS View

AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

ISRG : 398.82 (+0.60%)
ABC : 179.98 (-0.23%)
EW : 89.14 (-1.08%)
CHE : 565.52 (-0.50%)
Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

SYK : 334.68 (+0.21%)
ISRG : 398.82 (+0.60%)
EW : 89.14 (-1.08%)
CHE : 565.52 (-0.50%)
DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong

DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

ISRG : 398.82 (+0.60%)
EW : 89.14 (-1.08%)
DXCM : 131.36 (-0.42%)
CHE : 565.52 (-0.50%)
Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View

Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

BAX : 35.25 (+0.23%)
ISRG : 398.82 (+0.60%)
EW : 89.14 (-1.08%)
CHE : 565.52 (-0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Chemed Corporation purchases, operates and divests subsidiaries engaged in diverse business activities. The company's operating businesses are managed on a decentralized basis. Chemed currently operates as two wholly-owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS Healthcare segment provides...

See More

Key Turning Points

3rd Resistance Point 573.06
2nd Resistance Point 571.04
1st Resistance Point 568.28
Last Price 565.52
1st Support Level 563.50
2nd Support Level 561.48
3rd Support Level 558.72

See More

52-Week High 654.62
Fibonacci 61.8% 592.82
Fibonacci 50% 573.73
Last Price 565.52
Fibonacci 38.2% 554.64
52-Week Low 492.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar